CVAC News and Press, CureVac N.V. From 04/25/23

In 2022, ongoing business transformation driven by COVID-19 and flu clinical develop­ments in collaboration with GSK and successful broadening of oncology footprint Early 2023, strong validation of CureVac's proprietary mRNA technology platform from positive preliminary Phase 1 data in ...

2023-04-24 12:25:04 ET CureVac BV ( NASDAQ: CVAC ) is scheduled to announce Q4 earnings results on Tuesday, April 25th, before market open. The consensus EPS Estimate is -$0.29 and the consensus Revenue Estimate is $17.19M For further details see: CureVac BV Q4 2...

2023-04-24 10:24:40 ET Major earning expected before the bell on Tuesday include: General Electric ( GE ) General Motors ( GM ) McDonald's ( MCD ) 3M ( MMM ) Verizon Communications ( VZ ) For further details see: Notable earnings before Tu...

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 18, 2023 / CureVac N.V. (Nasdaq:CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), will report financial results, and provide business updates for the fourt...

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / March 28, 2023 / CureVac N.V. (NASDAQ:CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the voting results of the Company's...

2023-03-28 12:05:00 ET The World Health Organization (WHO) issued revised recommendations for prioritizing the use of COVID-19 vaccines on Tuesday, including healthy children and adolescents in a low-priority group for immunizations. The announcement follows a meeting of the agency&...

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / February 10, 2023 / CureVac N.V. (NASDAQ:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), announced today the closing of its follow-on public...

Dr. Mendila joins CureVac as Chief Development Officer with more than 20 years of global industry experience TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / February 1, 2023 / CureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medi...

CureVac ( NASDAQ: CVAC ) shares dropped ~7% Tuesday likely due to comments Pfizer ( PFE ) made earlier in the day that it expects a 64% drop in revenue from its COVID-19 vaccine. CureVac ( CVAC ) is developing its own mRNA COVID vaccine, and reported positive phase 1 res...

CureVac recognized as a Top 100 innovator in acknowledgment of the company's innovative strength and extensive intellectual property portfolio The company holds one of broadest intellectual property portfolios in mRNA technology TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / Janua...